NASDAQ:MRSN - Mersana Therapeutics News Headlines

$1.82
+0.02 (+1.11 %)
(As of 09/19/2019 08:23 AM ET)
Today's Range
$1.77
Now: $1.82
$1.89
50-Day Range
$1.83
MA: $2.63
$3.59
52-Week Range
$1.72
Now: $1.82
$12.90
Volume254,000 shs
Average Volume213,625 shs
Market Capitalization$87.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

Headlines

Mersana Therapeutics (NASDAQ MRSN) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Mersana Therapeutics Inc (NASDAQ:MRSN) Will Announce Quarterly Sales of $500,000.00 Brokerages Anticipate Mersana Therapeutics Inc (NASDAQ:MRSN) Will Announce Quarterly Sales of $500,000.00
www.americanbankingnews.com - September 3 at 1:46 AM
-$0.38 EPS Expected for Mersana Therapeutics Inc (NASDAQ:MRSN) This Quarter-$0.38 EPS Expected for Mersana Therapeutics Inc (NASDAQ:MRSN) This Quarter
www.americanbankingnews.com - September 1 at 6:18 PM
Mersana Therapeutics Inc (NASDAQ:MRSN) Receives Average Recommendation of "Buy" from BrokeragesMersana Therapeutics Inc (NASDAQ:MRSN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 31 at 2:34 AM
Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung CancerMersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung Cancer
finance.yahoo.com - August 20 at 6:31 PM
Calculating The Intrinsic Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Calculating The Intrinsic Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN)
finance.yahoo.com - August 12 at 8:08 PM
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call TranscriptMersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:35 PM
Mersana Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business UpdatesMersana Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Updates
finance.yahoo.com - August 8 at 10:26 AM
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2019 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing Second Quarter 2019 Financial Results and Business Updates
finance.yahoo.com - August 1 at 11:00 AM
Hedge Funds Have Never Been This Bullish On Mersana Therapeutics, Inc. (MRSN)Hedge Funds Have Never Been This Bullish On Mersana Therapeutics, Inc. (MRSN)
finance.yahoo.com - July 5 at 5:13 PM
Does Mersana Therapeutics, Inc. (NASDAQ:MRSN) Have A Particularly Volatile Share Price?Does Mersana Therapeutics, Inc. (NASDAQ:MRSN) Have A Particularly Volatile Share Price?
finance.yahoo.com - July 4 at 5:32 PM
New Finance VP at Mersana TherapeuticsNew Finance VP at Mersana Therapeutics
seekingalpha.com - June 12 at 12:40 PM
Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product StrategyMersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
finance.yahoo.com - June 12 at 12:40 PM
Mersana Therapeutics (MRSN) Presents At 2019 Jefferies Global Healthcare Conference - SlideshowMersana Therapeutics (MRSN) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 5:38 PM
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual MeetingMersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 1 at 9:40 AM
Mersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call TranscriptMersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 30 at 9:40 AM
Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual MeetingMersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 30 at 9:40 AM
Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare ConferenceMersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
finance.yahoo.com - May 30 at 9:40 AM
Mersana Therapeutics: ADC Specialist Pursuing A Novel TargetMersana Therapeutics: ADC Specialist Pursuing A Novel Target
seekingalpha.com - May 23 at 6:18 PM
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2019 Results - Earnings Call TranscriptMersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:33 AM
Mersana Therapeutics EPS of $0.70Mersana Therapeutics EPS of $0.70
seekingalpha.com - May 9 at 9:37 AM
Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business UpdatesMersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates
finance.yahoo.com - May 9 at 9:37 AM
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates
finance.yahoo.com - May 2 at 9:41 AM
Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferenceMersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 1 at 10:12 AM
Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019
finance.yahoo.com - March 25 at 9:15 AM
Mersana Therapeutics IncMersana Therapeutics Inc
www.bloomberg.com - March 19 at 9:55 AM
What Should You Know About Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Earnings Trajectory?What Should You Know About Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Earnings Trajectory?
finance.yahoo.com - March 12 at 5:37 PM
JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street SentimentJPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment
finance.yahoo.com - March 11 at 6:26 PM
Mersana Therapeutics (MRSN) CEO Anna Protopapas on Q4 2018 Results - Earnings Call TranscriptMersana Therapeutics (MRSN) CEO Anna Protopapas on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 9:36 AM
Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdatesMersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
www.nasdaq.com - March 8 at 10:01 AM
 Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
finance.yahoo.com - March 8 at 10:01 AM
Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare ConferenceMersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
finance.yahoo.com - March 6 at 9:50 AM
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 5 at 5:46 PM
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates
finance.yahoo.com - March 1 at 5:36 PM
The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For AscendisThe Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
www.msn.com - March 1 at 9:59 AM
Mersana Therapeutics down 29% premarket on stock offeringMersana Therapeutics down 29% premarket on stock offering
seekingalpha.com - March 1 at 9:59 AM
Mersana Therapeutics Announces Pricing of Public Offering of Common StockMersana Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 1 at 9:59 AM
Mersana Therapeutics Announces Proposed Public Offering of Common StockMersana Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 28 at 6:01 PM
Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare ConferenceMersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 20 at 9:57 AM
Mersana Therapeutics Inc.Mersana Therapeutics Inc.
www.barrons.com - January 23 at 9:25 AM
Mersana Therapeutics (MRSN) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowMersana Therapeutics (MRSN) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 10 at 5:08 PM
Mersana CEO details path forward after breakup with TakedaMersana CEO details path forward after breakup with Takeda
finance.yahoo.com - January 10 at 10:02 AM
Are Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Interest Costs Too High?Are Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Interest Costs Too High?
finance.yahoo.com - January 4 at 4:53 PM
Mersana Therapeutics to stop development of XMT-1522Mersana Therapeutics to stop development of XMT-1522
seekingalpha.com - January 4 at 10:06 AM
Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and BeyondMersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond
finance.yahoo.com - January 4 at 10:06 AM
Mersana to discontinue development of one cancer treatment to focus on anotherMersana to discontinue development of one cancer treatment to focus on another
finance.yahoo.com - January 4 at 10:06 AM
Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare ConferenceMersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:24 AM
Mersana Therapeutics appoints Dirk Huebner as Chief Medical OfficerMersana Therapeutics appoints Dirk Huebner as Chief Medical Officer
seekingalpha.com - November 27 at 10:05 AM
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical OfficerMersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
finance.yahoo.com - November 27 at 10:05 AM
Mersana Therapeutics (MRSN) CEO Anna Protopapas on Q3 2018 Results - Earnings Call TranscriptMersana Therapeutics (MRSN) CEO Anna Protopapas on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 13 at 4:29 PM
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business UpdatesMersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
finance.yahoo.com - November 13 at 9:06 AM
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel